/GALT
GALT Stock - Galectin Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$4.38-28.90%
$1.78 (-28.90%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+151.1%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GALT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.34 – $4.42
TARGET (TP)$11.00
STOP LOSS$4.03
RISK/REWARD1:18.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.96
52W High$7.13
52W Low$0.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-37,000 | $-33,000 | $-32,000 | $-41,000 | $-36,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-42,433,000 | $-38,072,000 | $-38,352,000 | $-30,179,000 | $-23,444,000 |
| Net Income | $-47,047,000 | $-41,066,000 | $-38,776,000 | $-30,527,000 | $-23,465,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 |
Company Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$6
Average Target
↑ 37.0% Upside
Now
$6
Low
$6
Average
$6
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 17th 2025 | H.C. Wainwright | Resumed | Buy | $6 |
Earnings History & Surprises
GALTBeat Rate
58%
Last 19 quarters
Avg Surprise
+2.3%
EPS vs Estimate
Beats / Misses
11/7
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.16vs$-0.16
Q2 24
-18.8%
$-0.19vs$-0.16
Q3 24
-25.0%
$-0.20vs$-0.16
Q4 24
+10.0%
$-0.18vs$-0.20
Q1 25
-18.8%
$-0.19vs$-0.16
Q2 25
+25.0%
$-0.15vs$-0.20
Q3 25
+25.0%
$-0.12vs$-0.16
Q4 25
-18.2%
$-0.13vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.20 | $-0.15 | +25.0% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.20 | $-0.18 | +10.0% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.16 | $-0.16 | 0.0% | = MET |
Q4 2023 | Nov 13, 2023 | $-0.16 | $-0.24 | -50.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.21 | $-0.15 | +28.6% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.20 | $-0.14 | +30.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.10 | $-0.17 | -70.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.19 | $-0.13 | +31.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.17 | $-0.11 | +35.3% | ✓ BEAT |
Latest News
Galectin Therapeutics Announces FDA Converted Co.'s Initial Request For In-Person Or Teleconference To Written Response, Says 'Based on FDA's written feedback, the Company believes there is alignment with the Agency on the patient population proposed for enrollment in a registration trial.'
📈 PositiveBenzinga•Dec 19, 2025, 01:03 PM
Galectin Therapeutics Secured $10M Line Of Credit
📈 PositiveBenzinga•Dec 19, 2025, 12:59 PM
Galectin Therapeutics shares are trading higher after HC Wainwright & Co. maintained the stock with a Buy rating and raised the price target from $6 to $11.
📈 PositiveBenzinga•Dec 17, 2025, 05:58 PM
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11
📈 PositiveBenzinga•Dec 17, 2025, 12:44 PM
PureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS
➖ NeutralBenzinga•Dec 5, 2025, 06:02 PM•Also:
Galectin Therapeutics Highlights Presentation Of Biomarker Analyses From NAVIGATE At AASLD 2025 Annual Meeting
➖ NeutralBenzinga•Nov 10, 2025, 01:09 PM
PureTech Health To Share New Data From Ongoing Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In r/rAML At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:18 PM•Also:
Galectin Beats Q2 Loss Estimates
📈 PositiveThe Motley Fool•Aug 14, 2025, 12:11 PM
Frequently Asked Questions about GALT
What is GALT's current stock price?
Galectin Therapeutics Inc. (GALT) is currently trading at $4.38 per share. The stock has moved -28.90% today.
What is the analyst price target for GALT?
The average analyst price target for GALT is $11.00, based on 1 analyst.
What sector is Galectin Therapeutics Inc. in?
Galectin Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GALT's market cap?
Galectin Therapeutics Inc. has a market capitalization of $0.28 billion, making it a small-cap company.
Does GALT pay dividends?
No, Galectin Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
DRTS
Alpha Tau Medical Ltd.
$5.07
Mkt Cap: $0.4B
DSGN
Design Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
RCKT
Rocket Pharmaceuticals, Inc.
$3.23
Mkt Cap: $0.3B
Explore stocks similar to GALT for comparison